Volume 5.09 | Mar 7

Cord Blood News 5.09 March 7, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
TOP STORY
Cord Lining-Mesenchymal Stem Cells Graft Supplemented with an Omental Flap Induces Myocardial Revascularization and Ameliorates Cardiac Dysfunction in a Rat Model of Chronic Ischemic Heart Failure
Scientists presented a restorative strategy that combines a fibrin graft containing human cord-lining mesenchymal stem cells and omental flap providing, thereby, cell-, structural-, and angiogenic support to the injured myocardium. [Tissue Eng Part A] Abstract

NEW STEMvision CB, BM & MPB Algorithms
PUBLICATIONS (Ranked by impact factor of the journal)

The Contribution of Stem Cell Therapy to Skeletal Muscle Remodeling in Heart Failure
Researchers investigated whether stem cell therapy with human amniotic fluid stem cells and rat adipose tissue stromal vascular fraction cells-GFP positive cells was able to produce favorable effects on skeletal muscle remodeling in a well-established rat model of right heart failure. [Int J Cardiol] Abstract

Modeling Dendritic Cell Vaccination for Influenza Prophylaxis: Potential Applications for Niche Populations
Investigators developed in vitro and in vivo models of dendritic cell (DC) immunotherapy for the prevention of influenza infection. Human cord blood (CB)-derived or mouse splenocyte-derived DCs were loaded with purified rHA protein. T-cell responses to HA-loaded CB DC were determined by ELISpot. [J Infect Dis] Abstract

Ocular Complications in Children within 1 Year after Hematopoietic Stem Cell Transplantation
Investigators studied the development of ocular complications in children within one year after hematopoietic stem cell transplantation. [JAMA Ophthalmol] Abstract | Press Release

The Use of Human Amniotic Fluid Mesenchymal Stem Cells as the Feeder Layer to Establish Human Embryonic Stem Cell Lines
Researchers tested human amniotic fluid mesenchymal stem cells as feeder cells to support the growth of human embryonic stem cells. [J Tissue Eng Regen Med] Abstract

Microbial Contamination of Hematopoietic Progenitor and Other Regenerative Cells Used in Transplantation and Regenerative Medicine
Microbial contamination of hematopoietic progenitor cells (HPCs) and other regenerative cells used in transplantation and regenerative medicine can occur during collection and after in vitro manipulation, including purging, cryopreservation, thawing, and infusion. Microbiologic culture findings on consecutive HPCs and other cell preparations at a single institution derived from peripheral blood, marrow, cord blood, and mesenchymal stromal cells during all phases of manipulation were retrospectively examined. [Transfusion] Abstract

Benzo[a]pyrene Induces Oxidative Stress and Endothelial Progenitor Cell Dysfunction via the Activation of the Nuclear Factor-κB Pathway
Researchers evaluated the effects of benzo[a]pyrene (BaP) on the function and pro-inflammatory response of human endothelial progenitor cells (EPCs). EPCs were isolated from umbilical cord blood and treated with different concentrations of BaP. [Int J Mol Med] Abstract

Persistence of Anti-HLA Antibody after Cord Blood Transplantation Engraftment in Acute Myelogenous Leukemia: A Potential Marker of Minimal Residual Disease, but Not a Significant Factor in Secondary Humoral Engraftment Failure
The presence of pre-transplant anti-HLA antibodies in recipients of cord blood transplantation (CBT) is associated with failed engraftment. However, only a small number of studies have reported that recipient-derived anti-HLA antibodies persist after CBT and have potential impact on the outcome. Of 61 patients who underwent HLA-mismatched CBT, three patients were identified as having anti-HLA antibodies not corresponding to HLA antigens in the transplanted CB. All patients achieved successful engraftment. [Int J Hematol] Abstract

Thymic Function Recovery after Unrelated Donor Cord Blood or T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation Correlates with Leukemia Relapse
Long-term T-cell immune reconstitution largely relies on the generation of new T cells in the recipient thymus, which can be evaluated through signal joint and beta T-cell-receptor excision circles quantification. Investigators studied two groups of 33 and 24 children receiving, respectively, hematopoietic stem cell transplantation from an HLA-haploidentical family donor or an unrelated cord blood donor, for both malignant and non-malignant disorders. [Front Immunol] Full Article

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells

REVIEWS
Expanded Indications for Allogeneic Stem Cell Transplantation in Patients with Myeloid Malignancies
Hematopoietic stem cell transplantation (SCT) can be curative for myeloid malignancies such as acute myeloid leukemia. Advancements in human leukocyte antigen typing and supportive care have improved the risk-benefit ratio for SCT, expanding its indications. [Curr Opin Hematol] Abstract

Stem Cells for Drug Developers | March 19-21, 2013 | Boston
INDUSTRY NEWS

Saneron and USF Patent Method for Umbilical Cord Blood Cell Use
Researchers at Saneron CCEL Therapeutics, Inc. (Saneron) and the University of South Florida (USF) have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord. [Newswise, Inc.] Press Release

United Therapeutics Moves Forward towards a Phase I Study of Pluristem’s PLX-PAD Cells for Pulmonary Arterial Hypertension
Pluristem Therapeutics Inc. announced that following favorable preclinical studies, United Therapeutics Corporation intends to begin a human Phase I clinical trial in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with pulmonary arterial hypertension upon approval by the Australian regulatory authorities. [Pluristem Therapeutics Inc.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of Drugs, Chemicals, and the Environment
May 29-31, 2013
New York, United States

View our events page to see a complete list of events in the cord blood community.
JOB OPPORTUNITIES

Early Stage Researcher PhD Posts – DECIDE ITN (The University of Birmingham)

Postdoctoral Fellow – Stem Cell Biology (Washington University School of Medicine)

Postdoctoral Fellow (University of Michigan)

Postdoctoral Position – Hematopoietic Stem Cells and Stem Cell Aging (Cincinnati Children’s Hospital Research Foundation)

Postdoctoral Researcher – NK/T Cells (The Ohio State University – Comprehensive Cancer Center)

Postdoctoral Position – Stem Cell Research (University of Washington)

Lecturer or Reader – Associate Professor (University of Reading)

Cord Blood Laboratory Manager (Puget Sound Blood Center)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us